ArriVent BioPharma, Inc. Common Stock

AVBP · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$34,978-$31,399-$64,387-$20,633
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$3,716$3,311$2,271$952
Change in WC-$4,536$1,964-$5,892$3,529
Other Non-Cash$0$0$0$0
Operating Cash Flow-$35,798-$26,124-$68,008-$16,152
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases-$90,369-$21,568-$9,817-$194,164
Inv. Sales/Matur.$39,609$35,478$46,638$0
Other Inv. Act.$0$0$0$1,699
Investing Cash Flow-$50,760$13,910$36,821-$192,465
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$86,465$75,341$6,759$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0-$227$0$55
Financing Cash Flow$86,465$75,114$6,759$55
Forex Effect$0$0$0$0
Net Chg. in Cash-$93$62,900-$24,428-$208,562
Supplemental Information
Beg. Cash$112,765$49,865$74,293$282,855
End Cash$112,672$112,765$49,865$74,293
Free Cash Flow-$35,798-$26,124-$68,008-$16,152